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a  b  s  t  r  a  c  t
Cytotoxic  chemotherapy  remains  central  to the  treatment  of  all  subtypes  of metastatic  breast  cancer
(MBC). We  review  evidence-based  chemotherapy  options  for  women  with  MBC after  an  anthracycline
and  a taxane  including  re-challenge  with  anthracycline  or taxane,  capecitabine,  eribulin  and ixabepilone
as a single  agent  or combination  with  capecitabine  (not  approved  in the EU);  and  the  vinca  alkaloid
vinﬂunine as  single  agent  or combined  with  either  capecitabine/gemcitabine  (also  not  approved  EU  or
USA).  Etirinotecan  pegol,  comprising  irinotecan  bound  to polyethylene  glycol  by a biodegradable  linker,eywords:
etastatic breast cancer
nthracycline
axane
apecitabine
ribulin
tirinotecan pegol
is  a new  cytotoxic  agent  for p
II  studies;  it  has  been  further  
novel  targets  or  modes  of  deliv
predictive  biomarker(s).
©  2016  The  Authors.  Pu
Abbreviations: 5FU, 5-ﬂuorouracil; A, anthracycline; BEACON, BrEAst Cancer Outcom
;  CTCs, circulating tumor cells; CI, conﬁdence interval; CHF, congestive heart failure; DF
hysician’s Choice vs E7389; EPR, enhanced permeability and retention; NKTR-102, etirino
eeks;  FDA, Food and Drug Administration; 1L, ﬁrst-line; HFS, hand–foot syndrome; HR, h
o-treat;  MBC, metastatic breast cancer; nab-P, nab-paclitaxel; NPLD, non-pegylated dox
ate;  OS, overall survival; PPE, palmer-plantar erythrodysesthesia; PLD, pegylated liposo
uality of life; T, taxanes; TTP, time to tumor progression; TOP1, topoisomerase I; T-DM1, t
reast  cancers; US, United States.
∗ Corresponding author. Fax: +44 113 206 8474.
E-mail addresses: C.J.Twelves@leeds.ac.uk (C. Twelves), M.Jove@leeds.ac.uk (M.  Jove), 
ttp://dx.doi.org/10.1016/j.critrevonc.2016.01.021
040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. T
http://creativecommons.org/licenses/by-nc-nd/4.0/).atients  with  MBC  that  has  achieved  encouraging  response  rates  in  phase
evaluated  in  the  phase  III BEACON  trial.  New  cytotoxics  should  address
ery,  achieve  meaningful  improvements  in outcomes  and seek to  identify
blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
es with NKTR-102; BRCA, breast cancer gene; CALGB, cancer and leukemia Group
I, disease-free interval; EMBRACE, Eisai Metastatic BReast Cancer study Assessing
tecan pegol; EMA, European Medicines Agency; EU, European Union; q21d, every 3
ormone receptor; HER2, human epidermal growth factor receptor 2; ITT, intention-
orubicin; NR, not reported; NS, not statistically signiﬁcant; ORR, overall response
mal doxorubicin; PN, peripheral neuropathy; PFS, progression free survival; QOL,
rastuzumab emtansine; TPC, treatment of physicians’ choice; TNBC, triple-negative
andrea.gombos@bordet.be (A. Gombos), ahmad.awada@bordet.be (A. Awada).
his is an open access article under the CC BY-NC-ND license
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. Introduction
Despite advances in the diagnosis and treatment of women
ith early breast cancer, globally more than 500,000 women  die
nnually from the disease, reﬂecting the ongoing need for better
reatment for women with metastatic breast cancer (MBC) (World
ealth Organization, 2014). Increasingly, we appreciate the hetero-
eneity of MBC  in terms of its biology, but when making systemic
reatment decisions, there are four main subgroups: hormone
eceptor (HR)-positive (≥65% of invasive breast cancers), which
omprise luminal A cancers that are human epidermal growth fac-
or receptor 2 (HER2)-negative and low Ki 67 and luminal B cancers
hat are HER2-positive or high Ki 67; HER2-positive (15–20%); and
R- and HER2-negative or triple-negative breast cancers (TNBC;
5–20%) (Lakhani et al., 2012). The median survival of patients with
BC is approximately 24 months, but is better in patients with HR-
ositive and HER2-positive tumors than those with TNBC (André
nd Zielinski, 2012; Kennecke et al., 2010; Bonotto et al., 2014).
While there are major differences in the treatment of patients
ith MBC, chemotherapy remains fundamental to the manage-
ent of women with all molecular subtypes. For those with TNBC,
hemotherapy offers the only systemic treatment option, but they
re not the only group in whom chemotherapy is important.
atients with HR-positive disease, the biggest MBC  subgroup, usu-
lly receive successive lines of endocrine therapy as long as they
espond (Fedele et al., 2012). Everolimus appears to delay endocrine
esistance (Baselga et al., 2012); palbociclib also enhances the efﬁ-
acy of endocrine therapy (letrozole or fulvestrant) (Finn et al.,
014). Ultimately, when endocrine options have been exhausted,
r the patient develops more aggressive disease, chemotherapy
ecomes relevant. Similarly, patients with HER2-positive MBC
eceive targeted therapies (e.g., trastuzumab, pertuzumab, lapa-
inib) usually in combination with chemotherapy; trastuzumab
mtansine (T-DM1) is given as monotherapy, but is a conjugate that
ncludes the cytotoxic agent maytansine (Krop et al., 2014). Inde-
endent of the molecular phenotype, chemotherapy will, therefore,
e an option at some point for most patients with MBC. Early reports
f immunotherapy targeting PD-1/PD-L1 and antiandrogens are
ncouraging in subsets of TNBC, but these are not ready to replace
hemotherapy (Emens et al., 2015; Traina et al., 2015).
Improving overall survival (OS) and/or quality of life (QOL)
re key aims in treating patients with MBC. A perception may
xist when considering chemotherapy: that the choice is between
fﬁcacy with treatment or better QOL without treatment. This mis-
onception ignores the complications of the underlying disease on
OL. Our aim should, therefore, be to improve both quantity and
uality of life for women with MBC.
Another guiding principle in treating patients with MBC  is that
ingle-agent sequential treatment is usually preferable to combina-
ion treatments (Fedele et al., 2012). The latter frequently achieves
igher response rates, but at the cost of increased toxicity and
ittle impact on OS. Although single-agent sequential treatment
s accepted as “standard,” the evidence from randomized trials
egarding which drug to use following anthracycline and taxane
as been surprisingly limited, especially for “old” agents such as
inorelbine and gemcitabine (Oostendorp et al., 2011). As a result,
uidelines do not specify the sequence in which drugs should be
iven.
In contrast to the use of endocrine and HER2 targeted thera-
ies, where biomarkers predictive of efﬁcacy (e.g., ER, HER2 status)
re integral to treatment decisions, similar biomarkers are not
ell deﬁned in the context of speciﬁc chemotherapy. The data are
rguably strongest for patients with BRCA-mutated MBC  in whom
arboplatin was substantially more effective and better tolerated
han docetaxel as ﬁrst-line treatment (Tutt et al., 2014a). The abil-
ty to “personalize” the choice of cytotoxic to the individual patientogy/Hematology 100 (2016) 74–87 75
and her cancer more widely would represent a major paradigm
shift.
Drug resistance is, without doubt, the primary impediment to
successful treatment of patients with MBC  (Perez, 2009). With the
increased use of anthracyclines (although with less cumulative
doses) and taxanes in the (neo) adjuvant setting, a growing propor-
tion of patients with MBC  have pretreated and/or drug-resistant
disease (Perez, 2009). Usual practice after an anthracycline and
taxane has been to favor agents from a class not previously admin-
istered, with the expectation that the cancer is less likely to be
cross-resistant to such treatment. The need remains, therefore, for
new and better chemotherapy for women  with MBC, almost half
(43%) of whom receive >3 lines of chemotherapy (Ribeiro et al.,
2012). New agents should preferably belong to a novel class, or
have a novel mechanism of action, improve OS while maintaining
or improving QOL when given as monotherapy, and be well toler-
ated and supported by sound evidence that would ideally include
a predictive biomarker.
This article does not attempt to be a comprehensive review of
chemotherapy in MBC. Rather, we focus on single-agent treatment
following an anthracycline and a taxane, limiting ourselves to the
most widely used drugs and emerging chemotherapy options.
2. Current therapeutic options for anthracycline- and
taxane pretreated MBC
Until recently, therapeutic options after failure of anthracycline
and taxane were limited (André and Zielinski, 2012). Currently,
widely approved monotherapies for later-line treatment of MBC
include capecitabine, eribulin, nanoparticle albumin-bound (nab)-
paclitaxel, and ixabepilone (in the U.S.); vinorelbine is approved
after an anthracycline (but not speciﬁcally a taxane) in Europe.
Pegylated liposomal doxorubicin (PLD) and single agents such
as gemcitabine, platinum agents, and irinotecan are also used
(Table 1). There is no agreement regarding the preferred agents
and their sequence; a recent consensus report recognized that evi-
dence is strongest for eribulin and capecitabine (Partridge et al.,
2014). Likewise, carboplatin/cisplatin chemotherapy seems to be
especially active in patients with BRCA 1/2 mutations or for TNBC
with DNA repair deﬁciency (Isakoff et al., 2015). The TNT random-
ized phase III trial compared carboplatin with docetaxel in 376
patients with metastatic/locally recurrent advanced TNBC and/or
BRCA1/2 positive tumors (Tutt et al., 2014b). In the 43 BRCA posi-
tive patients the ORR was  68% vs 33% and PFS of 6.8 vs 3.2 months
in the carboplatin vs docetaxel arms, respectively. Such differences
were not, however, seen in the overall population (ORR of 31.4
vs 35.6% and PFS of 3.1vs 4.5 months in the carboplatin vs doc-
etaxel arms, respectively). Indeed, many of the current options
after anthracycline and taxane have not been compared in ran-
domized clinical trials, and cross-trial comparisons can be difﬁcult.
Consequently, treatment decisions are frequently based on per-
sonal experience, prior therapy, adverse event proﬁles, and patient
preference (Ribeiro et al., 2012).
2.1. Rechallenge with, or reformulation of, an anthracyclines or
taxane
There is a paucity of evidence documenting the efﬁcacy of
rechallenge with a conventional anthracycline or taxane in patients
with MBC  (Ribeiro et al., 2012; Partridge et al., 2014; Isakoff et al.,
2015; Tutt et al., 2014b; Venturini et al., 1996). Although responses
have been described, most studies are single-center cohorts, small
phase II trials, or retrospective analyses of phase III studies; such
trials often do not specify previous adjuvant chemotherapy, and
patients with anthracycline- and taxane-resistant or refractory dis-
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Table 1
At a glance: most common agents used in anthracycline- and taxane-pretreated metastatic breast cancer.
Drug Differentiating
characteristics related
to mechanism or class
Key messages from clinical trials Gaps Role and issues in clinical practice
Pegylated (PLD) and
non-pegylated
liposomal
doxorubicin
Doxorubicin
hydrochloride
encapsulated in
liposomes with or
without surface-bound
pegylation
• Similar efﬁcacy but less
cardiotoxicity than conventional
anthracyclines in ﬁrst-line
setting
•  Myelosuppression, stomatitis,
and PPE major toxicities
associated with use
Limited data to suggest
role of anthracycline
rechallenge in MBC  and
in  later stage MBC
• May consider use after
non-anthracycline–containing
adjuvant therapy or after limited
doses of anthracycline-based
adjuvant therapy
• Cumulative cardiotoxicity
precludes or limits the use in
patients with cardiac risk or near
threshold doses
nab-paclitaxel Paclitaxel in
albumin-bound
complexes via
nanotechnology
platform
(nab-technology)
• Until recently, thought to be
associated with improved ORR
and PFS over that of
conventional taxanes (q 3 week
schedule)
•  Activity suggested in
taxane-resistant MBC  (i.e., not
complete cross-resistance)
• Less neutropenia but greater PN
than paclitaxel (albeit possibly
shorter-lived)
• Signiﬁcant alopecia
Recent trial (CALGB
40502 trial) shows no
better efﬁcacy and
more toxicity than
paclitaxel; limited data
to suggest role of
taxane rechallenge in
MBC
• Advantage of short infusion time
and “lack” of premedication
(especially in diabetic patients
and those with prior history of
paclitaxel-induced infusion
reaction) but neuropathy,
alopecia, and cost preclude its
broad use
• Cumulative PN precludes its use
in  patients with residual
(baseline) neuropathy or history
of  severe PN with previous agent
Capecitabine Prodrug that is
enzymatically
converted to the
antimetabolite 5FU
• Convenient oral therapy devoid
of appreciable alopecia
• Dosage adjustments often
necessary even at recommended
reduced dose of
2000 mg/m2/day
•  HFS (20%) may  be treatment
limiting; fatigue and diarrhea
other common toxicities
•  Dose reduction required in
patients with renal dysfunction
Role in speciﬁc
molecular subtypes
unclearbeneﬁt possibly
limited to hormone
receptor-positive MBC
• Approved as monotherapy for
the treatment of MBC  after
failure of both A and T
•  Cumulative PPE may  limit
duration of therapy or require
dose modiﬁcation and treatment
delays over time
•  Option in women who want to
avoid alopecia or concerned
about lifestyle interruptions and
in elderly patients
Ixabepilone Epothilone (new
class)−non-taxane
tubulin polymerizing
agent
• Modest phase II activity noted in
A-/T- and capecitabine resistant
(ORR, 11–12%; TTP/PFS, 2.2–3.1
months)
•  Toxicity proﬁle not all that
different than taxanes in
resistant population (most
common grade 3/4: neutropenia
(50%), neuropathy (14%), and,
alopecia (>80%); fatigue also an
issue)
•  Neuropathy is major
dose-limiting AE and can be
permanent in some
• Important to adjust dose in
patients with mild to moderate
hepatic dysfunction
Recent trial (CALGB
40502 trial) suggests
less effective than
paclitaxel with greater
neuropathy
• Approved as monotherapy for
the treatment of metastatic or
locally advanced breast cancer
after failure of A, T, and
capecitabine
•  Approved in combination with
capecitabine for treatment of
metastatic or locally advanced
breast cancer resistant to A and
T or T and A contraindicated
• Possible role in TNBC (ORR, 18%)
•  Not approved by EMA as beneﬁt
thought not to outweigh risk
(speciﬁcally neuropathy)
• Cumulative PN precludes its use
in  patients with residual
(baseline) neuropathy or history
of  severe PN with previous agent
Eribulin Synthetic analog of
natural murine
product; binds to a
unique site on tubulin
• Survival beneﬁt in late-line
regimen after treatment with A,
T  (and usually capecitabine)
compared to TPC; TTP and ORR
also favored eribulin
• Eribulin at least as effective as
capecitabine when compared as
single agents
• PN and fatigue generally
manageable
•  Neutropenia and fatigue (all
grades) in ∼50% of patients, but
febrile neutropenia uncommon
• Dose reductions, delays, and
interruptions somewhat
common in clinical trials mainly
due to neutropenia
• Beneﬁts of eribulin
maintained across
molecular subtypes,
but most robust in
patients with
HER2-negative
disease; efﬁcacy
appears greatest in
patients with TNBC
• Efﬁcacy retained in
older patients
• Approved for use in US after A
and T and two previous
therapies for MBC; in EU,
positive opinion for use earlier
in MBC  (after one previous
chemotherapy)
• Unsure how to best incorporate
agent into standard algorithms
but provides evidenced base
support for treatment after A, T,
and as an alternative to
capecitabine
• Pre-existing PN does not
preclude use of eribulin
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Table  1 (Continued)
Drug Differentiating
characteristics related
to mechanism or class
Key messages from clinical trials Gaps Role and issues in clinical practice
Vinorelbine Second-generation
vinca alkaloid
• Phase III trial (vs
gemcitabine-capecitabine
combination) in A-/T-resistant
MBC provided 25% ORR and
median PFS of 4 months
•  Relatively well tolerated;
however, signiﬁcant
neutropenia (>50% grade 3/4;
∼11% febrile neutropenia risk)
• Often require central venous line
due to its vesicant properties
•  Inconvenient dosing regimen
(weekly regimen)
Majority of data in
anthracycline-resistant
disease; wide range of
ORR in phase II studies;
only one phase III trial
vs combination (not
other monotherapy)
• Cumulative PN precludes its use
in patients with residual
(baseline) neuropathy or history
of  severe PN with previous agent
•  Constipation and abdominal
complaints can be particularly
bothersome side effects
Gemcitabine Pyrimidine nucleoside
analogue
• Most effective when
administered with a taxane
(ﬁrst-line) or carboplatin
(later-lines)
•  Myelosuppression (neutropenia
and thrombocytopenia) most
common grade 3/4 toxicities;
thrombocytopenia may  be dose
limiting
•  Liver enzyme elevation may
limit the dose intensity
Lack of demonstrable
activity as
monotherapy in
A-/T-resistant MBC
• Limited data supporting use as
monotherapy in MBC
• Use caution in patients with
history of signiﬁcant
myelosuppression, in particular
thrombocytopenia, from prior
therapies
Platinum  agents Induces DNA adduct
formation
• Activity in patients with MBC
associated with germline BRCA
mutations
•  Activity in combination
(gemcitabine, 5FU, vinorelbine)
Lack demonstrable
activity as
monotherapy in
A-/T-resistant MBC
• Little, if any, role as single agents
in MBC  as both drugs
(carboplatin and cisplatin)
perform poorly in previously
treated patients
• Possible exception is TNBC
Vinﬂunine Third-generation vinca
alkaloid (novel
bi-ﬂuorinated
derivative of
vinorelbine); possible
additional
anti-angiogenic
properties
• Activity noted in A-/T-resistant
MBC (∼30% ORR); importantly, 7
of  18 responding patients failed
a  taxane within 3 months
• Phase II trial showed modest
activity in patients resistant to
vinorelbine
•  Superior preclinical activity vs
other vinca alkaloids
•  Less frequent and milder
neurotoxicity than vinorelbine
but signiﬁcant neutropenia,
fatigue, and constipation
•  Difﬁcult to use in combination
due to neutropenia
•  Combination with capecitabine
associated with prolonged PFS
over capecitabine alone but
associated with signiﬁcant grade
3/4 neutropenia and HFS;
combination with gemcitabine
less neurotoxic than
paclitaxel/gemcitabine; awaiting
OS data for both trials
Wide range of ORR in
phase II studies; unsure
if superior activity over
other vinca alkaloids
will translate into
signiﬁcant clinical
outcome differences
• Pending approval
• Less frequent and milder
neurotoxicity than earlier
generation vinca alkaloids
• More grade 3/4 neutropenia
although febrile neutropenia
was  not frequent (2.1–4.8% in
combination studies)
• It might have a role in some
patients in combination with
capecitabine (improve PFS and
QoL and a trend
• to OS)
Irinotecan Topoisomerase I
inhibitor−interferes
with DNA coiling
• Broad range of activity; lack
cross resistance and overlapping
toxicity
•  Data suggest cytotoxicity
dependent upon exposure time
with phase II trial demonstrating
weekly dosing associated with
better tolerability and improved
outcomes over every 3 week
dosing (due to prolonged SN38,
active metabolite)
• Myelosuppression and diarrhea
(dose limiting) are most
frequent toxicities
No randomized data in
A-/T-resistant MBC;
wide range of ORR in
phase II studies
• Not approved for use in MBC
•  Limited data to support its use as
monotherapy in MBC
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Table 1 (Continued)
Drug Differentiating
characteristics related
to mechanism or class
Key messages from clinical trials Gaps Role and issues in clinical practice
Etirinotecan pegol Unique, long-acting
polymer engineered
molecule consisting of
irinotecan bound to
polyethylene glycol
core by a
biodegradable linker
(proprietary polymer
conjugate technology)
• Pharmacokinetic proﬁle of drug
associated with reduced peak
SN38 concentrations and long
(50 days) half-life providing
continuous and sustained
exposure of active drug
•  Phase II trial suggests highly
active agent in A-/T- (and
capecitabine) resistant MBC
(ORR 29%; median PFS 4.9
months for ITT population and
5.6 months for every 21 day
regimen)
•  Most frequent AE is delayed
onset diarrhea (77% all grades;
23% grade 3; no grade 4);
delayed neutropenia can occur
Awaiting results of
phase III vs TPC
(BEACON trial); trial
will also provide
additional information
regarding biomarkers
based on circulating
tumor cells and further
elucidation on
frequency and severity
of diarrhea (strict
protocol deﬁned
guidelines regarding
dose modiﬁcation and
treatment)
• BEACON results reported in
2015 and if positive will provide
a statistically signiﬁcant
improvement in OS over TPC
comparator
• Exploratory analysis include
poor prognostic subgroups
(brain metastases and TNBC) and
translational biomarker studies
• Lacks common cumulative
and/or overlapping toxicities
(e.g. low bone marrow reserves,
neurotoxicity, and
cardiotoxicity) with other
established agents in MBC
• Due to long half-life of SN38,
treatment can be delayed to
allow for resolution of toxicity
(e.g.,  diarrhea) without
interruption of continuous
exposure to the active moiety
Abbreviations: 5FU, 5-ﬂuorouracil; A, anthracycline; BEACON, BrEAst Cancer Outcomes with NKTR-102; BRCA, breast cancer gene; CALGB, cancer and leukemia Group B;
E t; MBC
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ase may  be excluded (Venturini et al., 1996; Falkson et al., 1994;
ontenbal et al., 1998; Perez et al., 2001; Valero et al., 1998).
evertheless, patients with disease progression after a “substan-
ial” period following adjuvant anthracycline or taxane treatment
ay  beneﬁt from rechallenge with a conventional anthracycline or
axane in particular if a limited number of cycles of adjuvant anthra-
yclines and taxanes was received. Although cardiac toxicity can be
 concern, the cumulative anthracycline dose in standard adjuvant
egimens frequently leaves scope for rechallenge, especially with
pirubicin (Ryberg et al., 1998).
Another strategy is to rechallenge with a novel anthracycline
r taxane formulation. Most such clinical trials exclude patients
ith resistant or refractory disease (Table 2) (Keller et al., 2004;
l-Batran et al., 2006; Sparano et al., 2009; Gradishar et al., 2005;
lum et al., 2007a; Roy et al., 2009; Lobo et al., 2010; Gradishar
t al., 2012; Rugo et al., 2015; Yardley et al., 2013; Hamilton et al.,
013; Sun et al., 2014). It is also difﬁcult to determine whether
echallenge of new formulations is superior to conventional formu-
ations as data are limited, and direct comparisons were not made.
evertheless, liposomal anthracyclines as pegylated (PLD) and
on-pegylated (NPLD) doxorubicin have different pharmacokinetic
roﬁles (i.e., longer circulating half-life, enhanced drug accumula-
ion) from those of conventional anthracyclines and appear less
ardiotoxic whilst demonstrating similar efﬁcacy (Keller et al.,
004; Al-Batran et al., 2006; Sparano et al., 2009). With the avail-
bility of multiple other active cytotoxics, PLD or NPLD re-challenge
s, however, likely to be limited to patients with a long relapse-free
nterval following anthracycline-based adjuvant therapy, without
igniﬁcant cardiac impairment and limited access to alternative
rugs. Data to support PLD or NPLD rechallenge in later lines of
herapy are lacking.
Nab-paclitaxel is an albumin-based paclitaxel delivery system
eveloped as an alternative to solvent-based taxanes and exploiting
nhanced albumin uptake in tumors (Table 2) (Ribeiro et al., 2012;
radishar et al., 2005; Blum et al., 2007a; Roy et al., 2009; Lobo et al.,
010; Gradishar et al., 2012; Rugo et al., 2015; Yardley et al., 2013;
amilton et al., 2013; Sun et al., 2014). Nab-paclitaxel achieved
uperior overall response rate (ORR) and time to tumor progression, metastatic breast cancer; ORR, overall response rate; OS, overall survival; PFS,
thesia; T, taxane; TNBC, triple negative breast cancer; TPC, therapy of physicians’
(TTP) with less myelosuppression compared to 3-weekly pacli-
taxel in a phase III trial (Gradishar et al., 2005); it also compared
favorably with docetaxel in a randomized phase II trial (Gradishar
et al., 2012). In the phase III Cancer and Leukemia Group B (CALGB)
40502 study, however, nab-paclitaxel was  not superior to weekly
paclitaxel but did increase neurotoxicity (Rugo et al., 2015). In
terms of efﬁcacy after failure of a conventional taxane, deﬁned as
metastatic disease progression during taxane therapy or relapse
within 12 months of adjuvant taxane, responses to nab-paclitaxel
have been reported (Yamamoto et al., 2011); other phase II/III trials
have demonstrated activity (Table 2). Despite recent disappoint-
ing results, nab-paclitaxel is certainly an option in patients who
experience hypersensitivity reactions with conventional paclitaxel
(Table 1) (Yamamoto et al., 2011).
Finally, there are some data for taxane rechallengerechallange
combined with targeted therapy. The phase III AVADO trial of
bevacizumab plus docetaxel as ﬁrst-line therapy for MBC included
a small percentage of patients pretreated with adjuvanta taxane
(Miles et al., 2010). Although response rate and PFS were sig-
niﬁcantly superior in the bevacizumab arm, the combination did
not improve OS and is not, therefore, approved by the U.S. Food
and Drug Administration (FDA) or European Medicines Agency
(EMA) for MBC. Similarly, the CLEOPATRA clinical trial combined
trastuzumab and docetaxel with pertuzumab or placebo as ﬁrst
line for HER-2 positive MBC  included 23.2% and 22.6% of patients
pretreated with taxanes (Swain et al., 2015). Recently reported pos-
itive OS results have established the triplet as the recommended
ﬁrst-line treatment of choice for women  with HER2-positive MBC.
2.2. Capecitabine
Capecitabine, usually given as monotherapy, is commonly used
in patients with anthracycline- and taxane-refractory or −resistant
MBC, having been extensively evaluated in phase II trials in pre-
treated MBC  and to a lesser extent in randomized trials (Blum
et al., 1999; Blum et al., 2001; O’shaughnessy et al., 2001; Talbot
et al., 2002; Reichardt et al., 2003; Fumoleau et al., 2004; Blum
et al., 2007b; Miller et al., 2005). In a 2011 systematic review of
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Table 2
Anthracycline/taxane reformulations: clinical study outcomes.
Author/study
phase
Agents Patients Previous therapy ORR PFS OS Grade 3/4 toxicity Comments
≥2 MBC  (%) A T Resistant
Keller et al. (2004)
Phase III
PLD vs Vinorelbine
or Mitomicin C +
vinblastine
150 129 22 38%
√
/-
√
A/T 10% vs 12% 2.9 vs 2.5 mo
p = 0.11
11 vs 9 mo
p = 0.71
PLD arm had
more HFS (37%)
• Disease progression ≤6
mo  of previous T for MBC
•  17% of patients in both
arms were A-naïve
•  39% (arm A) and 35%
(arm B) were resistant to
A
Al-Batran et al.
(2006) Phase II
Single-arm PLD 79 35.4%
√ √
/- A 12.7% 3.6 mo;  95% CI
(2.7–6.4)
12.3 mo;  95% CI
(7.7–16.3)
HFS 5%
Neutropenia
17.1%
• Overall clinical beneﬁt
rate was 16.1% for
patients documented as
A resistance
Sparano et al.
(2009) Phase III
PLD + docetaxel vs
Docetaxel
378 373 0%
√
NR No 35% vs 26%
p = 0.0085
a9.8 vs 7 mo
p < 0.001
20.5 vs 20.6 mo
p = 0.81
HFS: 24% vs 0%
CHF: 5% vs 1%
• One previous
chemotherapy regimen
for MBC allowed
• 100% received (neo)
adjuvant A
Gradishar et al.
(2005) Phase III
nab-P vs Paclitaxel 229 225 17% vs 18%
√
/-
√
(adju-vant)
No 33% vs 19%
p = 0.001
a23 vs 16.9 wk
p = 0.006
NR Grade 4
neutropenia:
9% vs 22% PN:
10% vs 2%
• Eligibility criteria of
previous adjuvant T > 1
year
•  77% received previous A
Blum et al. (2007a)
Phase II
nab-P 100 mg/m2
vs nab-P
125 mg/m2
106 75 NR
(median 3
for MBC)
√
/-
√
/- T (89%; 78%
in MBC)
14% vs 16% 3 vs 3.5 mo 9.2 vs 9.1 mo Neutropenia:
18% vs 34% PN:
8% vs 19%
• Only Nab-P study with T
resistant patients
(progressed while
receiving T for MBC or
within 12 mo of
adjuvant)
•  ∼67% received A in
adjuvant setting
• 55% received T in MBC
Roy et al. (2009)
Phase II
nab-P +
gemcitabine
50 0% (1L)
√
/-
√
/- No 50% 7.9 mo  92% (6 mo) Neutropenia:
54% Fatigue:
28%
• 2% HER2-positive
patients
• 48% received previous A
•  30% received previous T
Lobo et al. (2010)
Phase II
nab-P +
gemcitabine +
bevacizumab
30 0% (1L) NR NR No 75.9% 10.4 mo 77.2% (18 mo)  PN: 3% Grade
3/4
neutropenia:
0%
• HER2-negative patients
•  ≥6 mo from
(neo)adjuvant therapy
•  62% chemo-naïve
80
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Table 1 (Continued)
Author/study
phase
Agents Patients Previous therapy ORR PFS OS Grade 3/4 toxicity Comments
≥2 MBC  (%) A T Resistant
Gradishar et al.
(2012) Phase II
nab-P 100 mg/m2
or 150 mg/m2
weekly vs nab-P
300 mg/m2 q21d vs
Docetaxel
76 74 76 74 0% (1L) NR NR No nab-P 150 49%
vs docetaxel
35%
nab-P 150 12.9
vs docetaxel 7.5
mo  p = 0.0065
nab-P 150 33.8
vs  docetaxel
26.6 mo
p = 0.688
Neutropenia:
nab-P 150 44%
vs docetaxel
94%; p = 0.001
PN: nab-P 22%
vs docetaxel
12%; p = NS
• No prior chemo for MBC
allowed
•  At least 1 year from prior
(neo)adjuvant therapy
•  39–
Rugo et al. (2015)
Phase III
Paclitaxel +/-
bevacizumab nab-P
+/-bevacizumab
Ixabepilone +/-
bevacizumab
283 271
245
0% (1L) NR
√
/- No (∼20%
DFI ≤1
year)
NR 10.6 vs 9.2 vs
7.6 mo
(Ixabepilone vs
paclitaxel;
p < 0.0001)
NR More adverse
events (PN,
fatigue, GI) in
nab-P arm;
least
hematologic
events in
ixabepilone
arm
• Bevacizumab planned to
all patients but optional
in 3/2011 (98% patients
received bevacizumab)
• 44% received previous T
-  At interim analysis,
ixabepilone failed in
comparison to paclitaxel;
accrual was closed
Yardley et al.
(2013) Phase II
nab-P + lapatinib 60 0% (25%
received 1
prior
regimen)
NR
√
/- No 53% 39.7 wk Not reached Diarrhea: 22%
Neutropenia:
22% PN: 3%
HER2-positive
• One previous
chemotherapy regimen
for MBC  allowed;
previous T  ≥12 mo
• Previous T-containing
regimens(Neo)adjuvant:
37%MBC: 7%
• (Neo)adjuvant + MBC: 3%
Hamilton et al.
(2013) Phase II
nab-P +
carboplatin +
bevacizumab
38 0% (1L)
√ √
NR 85% 9.2 mo  NR Neutropenia:
53%
Thrombocyto-
penia: 18% PN:
6%
• Only triple-negative
MBC  allowed
• 65% received previous
adjuvant A
• 62% received previous
adjuvant T
Sun et al. (2014)
Phase II
nab-P + cisplatin 73 ∼38% as 2L;
12% as ≥3L
√ √
No 67.1% 9.3 mo  26.9 mo  Neutropenia:
84% PN: 26%
• Eligibility criteria of
previous (neo)adjuvant
T  > 12 mo
• Previous T-containing
regimens
-(Neo)-adjuvant: 50% (>12
mo) -  MBC: 32% (> 3 mo)
•  Previous A-containing
regimens:
-  (Neo)-adjuvant: 73% -
MBC: 16%
•  Longer OS if no previous
T
Abbreviations: A, anthracyclines; CHF, congestive heart failure; CI, conﬁdence interval; DFI, disease-free interval; HFS, hand–foot syndrome; MBC, metastatic breast cancer; nab-P, nab-paclitaxel; NR, not reported; NS, not statically
signiﬁcant; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PN, peripheral neuropathy; q21d, every 3 weeks; T, taxanes.
aReported as time to progression.
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rials in which at least 80% of patients had received prior anthracy-
line and taxane, 1494 patients from 8 randomized phase II trials
nd 2 phase III trials were treated with single-agent capecitabine;
he response rate was 18%, median PFS 4.2 months, and OS 13.5
onths (Oostendorp et al., 2011). Results from more recent phase
II trials of capecitabine monotherapy as the control arm in sim-
lar populations reported comparable outcomes (Thomas et al.,
007a; Sparano et al., 2010; Kaufman et al., 2015; Baselga et al.,
014). For historical reasons, most capecitabine trials in MBC  are
rom molecularly-unselected populations. Recent data suggest that
apecitabine may  be more active in patients with HR-positive MBC
Glück et al., 2009).
Experience with capecitabine-based combinations has been
ixed. The addition of capecitabine to docetaxel improves OS vs
ocetaxel alone, but at the cost of greater toxicity (O’shaughnessy
t al., 2002). Although this is one of the few regimens that sig-
iﬁcantly improve OS in MBC, and does so without sacriﬁcing
OL, the combination was not widely adopted in clinical prac-
ice due to concerns over toxicity. The addition of ixabepilone to
apecitabine increased ORR and PFS, but not OS, and caused sub-
tantially more neuropathy and neutropenia (Table 3) (Thomas
t al., 2007a; Sparano et al., 2010). Nevertheless, the combination of
apecitabine and ixabepilone was approved by the FDA but not by
he EMA. Despite initial encouraging results with the combination
f capecitabine and sorafenib, a subsequent double-blind, placebo-
ontrolled phase III trial in patients with previously-treated MBC
omparing the combination with single-agent capecitabine failed
o meet its primary endpoint of improved PFS515 Finally, a phase II
tudy of capecitabine and eribulin in 42 patients with previously-
reated MBC  reported an ORR of 42% and PFS of 7.2 months; this
fﬁcacy was almost identical to that previously reported with
apecitabine and docetaxel, but with superior tolerability and no
nexpected toxicities (Twelves et al., 2014a). Of note, the median
umber of cycles was 8 (range 1–46) and seven patients (16.2%)
eceived >30 cycles of the combination.
. Newer antimicrotubule agents
.1. Ixabepilone
The epothilones are structurally distinct from taxanes and rep-
esent a new class of microtubule inhibitors; importantly, they have
reclinically promising activity in taxane-resistant tumors (Table 3)
Thomas et al., 2007a; Sparano et al., 2010; Perez et al., 2007;
homas et al., 2007b; Aogi et al., 2013; Smith et al., 2013). Ixabepi-
one, a semi-synthetic analog of epothilone B, is the ﬁrst epothilone
o be approved by the FDA as a single agent after failure of anthra-
ycline, taxane, and capecitabine; it was also approved by the
DA in combination with capecitabine in patients with previously-
reated MBC  as described above. Ixabepilone has not, however,
een approved by the EMA  due to concerns about its therapeu-
ic index, especially the risk of neuropathy (European Medicines
gency, 2014). Some support for the combination of ixabepilone
nd capecitabine comes from a pre-planned pooled analysis of 2
rials (Thomas et al., 2007a; Sparano et al., 2010), in which patients
ith TNBC (n = 443) had superior ORR (31% vs 15%), longer PFS (4.2
s 1.7 months), and a trend toward longer survival (10.3 vs 9.0
onths) vs single-agent capecitabine (Rugo et al., 2008).
In an attempt to improve its therapeutic index in MBC, the stan-
ard 3-weekly regimen of ixabepilone was compared to weekly
reatment (days 1, 8, 15 every 28 days); 3-weekly ixabepilone
as more effective than weekly treatment, albeit with consid-
rably more toxicity and patient withdrawals due to toxicity
Smith et al., 2013). In the ﬁrst-line setting, a large randomized
rial comparing 3-weekly ixabepilone to weekly paclitaxel andogy/Hematology 100 (2016) 74–87 81
weekly nab-paclitaxel, each combined with bevacizumab, closed
recruitment to the ixabepilone arm at the ﬁrst interim analy-
sis when the comparison of ixabepilone vs paclitaxel crossed the
boundary for futility (Table 2) (Rugo et al., 2015). Ixabepilone
was signiﬁcantly less effective than paclitaxel (median PFS 7.6
vs 10.6 months, respectively; hazard ratio (HR), 1.53 [95% CI,
1.24–1.90]; p < 0.0010); weekly paclitaxel caused less peripheral
sensory neuropathy (16% and 25%, respectively) but more grade 3/4
neutropenia (47% and 7% with paclitaxel and nab-paclitaxel, respec-
tively). Questions remain, including whether the regimens chosen
(based on phase II trials) were optimal; whether toxicity and con-
sequent dose reductions (45% of patients in the nab-paclitaxel arm)
account for reduced efﬁcacy; and whether bevacizumab may  have
had a differential effect between the treatment arms. Overall, the
role of ixabepilone as single agent or combined with capecitabine
as treatment of MBC  remains unclear and the risk-beneﬁt balance
challenging.
3.2. Eribulin
A more signiﬁcant addition to the list of novel agents for the
treatment of chemotherapy-resistant/pretreated MBC  is eribulin
mesylate. As a structurally simpliﬁed synthetic analog of the nat-
ural marine product halichondrin B, eribulin distinguishes itself
from other antimicrotubule agents by its unique interaction with
tubulin, inhibiting microtubule growth with no apparent effect on
depolymerization, unlike other cytotoxic agents directed at the
microtubule (Kuznetsov et al., 2004). This novel mechanism of
action may  explain the activity of eribulin in taxane-resistant tumor
cell lines (Kuznetsov et al., 2004). Encouraging activity was seen in
an initial phase II study, but at the price of frequent neutropenia
leading to frequent dose omissions (Vahdat et al., 2009). Modiﬁca-
tion of the regimen from administration on days 1, 8, and 15 every
28 days to a days 1 and 8 every 21-day regimen reduced treatment
omissions and maintained activity, although neutropenia remained
common (Vahdat et al., 2009; Cortes et al., 2010).
The global multicenter phase III trial, EMBRACE (Eisai Metastatic
BReast Cancer study Assessing physician’s Choice vs E7389) ran-
domized patients with locally recurrent or MBC  previously treated
with 2–5 prior chemotherapy regimens, including anthracycline
and taxane, to eribulin or single-agent “treatment of physicians’
choice” (TPC) (Cortes et al., 2011). The study achieved its primary
endpoint with a statistically and clinically signiﬁcant increase in
OS of 2.5 months with eribulin; TTP and ORR supported the clinical
beneﬁt of eribulin over TPC. The most common grade 3–4 toxicities
were neutropenia, although febrile neutropenia was uncommon
(8% of patients), as was  reversible peripheral neuropathy (Table 3).
An updated survival analysis after 77% of events, requested by regu-
lators, conﬁrmed the primary analysis with eribulin beneﬁts being
maintained across all molecular subtypes of MBC. EMBRACE estab-
lished eribulin as the only cytotoxic to signiﬁcantly prolong survival
in patients with MBC  previously treated with both anthracycline
and taxane and led to its approval as third-line or later treatment
in this setting. The novel study design, with a TPC control arm and
OS primary endpoint, was  commended by the FDA (Donoghue et al.,
2012).
A second phase III trial, Study 301, compared eribulin with
capecitabine in a less heavily pretreated population, who had
nevertheless received anthracycline and taxane (Kaufman et al.,
2015).The trial failed to meet its co-primary endpoints of improved
OS, although there was a trend favoring eribulin (HR 0.88 [95% CI,
0.77–1.00]; p = 0.056). Neutropenia was common, but febrile neu-
tropenia was  seen even less frequently (<3%) than in the EMBRACE
trial; QOL was  similar in both arms (Cortes et al., 2015a,b). Of
note, there was  no difference in PFS between the two arms. Recent
preclinical work has suggested that eribulin may alter tumor biol-
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Table 3
New-agent chemotherapy outcomes in pretreated metastatic breast cancer.
Author/study phase Agent Patients Prior therapy ORR PFS OS Grade 3/4 toxicity
≥2 MBC  (%) Median for MBC
(no.)
A T C
Perez et al.
(2007)/Phase II
Ixabepilone 126 88% NR
√ √ √
11% 3.1 mo  8.6 mo  Neutropenia: 54% PN:
14% FN: <1%
Thomas et al.
(2007b)/Phase II
Ixabepilone 49 86% NR
√ √
NR 12% 2.2 mo  7.9 mo  Neutropenia: 53% FN:
6% PN: 12%
Aogi et al. (2013)/Phase
II (Japan)
Ixabepilone 52 73% NR
√ √
NR 11.5% 2.8 mo  12.4 mo  Neutropenia: 83% FN:
6% PN: 19%
Smith et al.
(2013)/Phase II
Ixabepilone q21d vs day
1,8,15 q28d
91 85 NR 2
√
/-
√
/-
√
/- 13.5% vs 7.6% 5.3 vs 2.9 mo  16.1 vs 13.9 mo Neutropenia: 38% vs 6%
FN: 2% vs 0% PN: 16% vs
9%
Thomas et al.
(2007a)/Phase III
Ixabepilone + capecitabine
vs Capecitabine
369 368 46% 43% NR
√ √
NR 35% vs 14%
(p < 0.0001)
5.8 vs 4.2 mo
(p = 0.0003)
NR Neutropenia: 68% vs
11% PN: 23% vs 0%
Fatigue: 9% vs 3% Toxic
deaths: 3% vs 1% HFS:
18% vs 17%
Sparano et al.
(2010)/Phase III
Ixabepilone + capecitabine
vs capecitabine
609 612 18.3% 17.5% NR (48% received 1
previous regimen
for MBC85)
√ √
– 43% vs 29%
(p < 0.0001)
6.2 vs 4.2 mo
(p = 0.0005)
16.4 vs 15.6 mo
(p = 0.116; p = 0.023
with Cox regression)
Neutropenia: 73% vs 9%
FN: 7% vs <1% PN: 25%
vs 1% HFS: 21% vs 20%
Cortes et al.
(2010)/Phase II
Eribulin 299 NR NR (median 4
reported includes
adjuvant)
√ √ √
9.3% 2.6 mo  10.4 mo  Neutropenia: 54% FN:
6% PN: 7%
Cortes et al.
(2011)/Phase III
Eribulin vs TPC 508 254 100% (per
eligibility criteria)
NR (median 4
reported includes
adjuvant)
√ √ √
/- 12% vs 5%
(p = 0.002)
3.7 vs 2.2 mo
(p = 0.137)
13.1 vs 10.6 mo
(p = 0.041)
Neutropenia: 45% vs
21% FN: 5% vs 2% PN:
8% vs 2%
Kaufman et al.
(2015)/Phase III
Eribulin vs Capecitabine 554 548 29% 28% NR
√ √
– 11% vs 12% 4.1 vs 4.2 mo
(p = 0.3)
15.9 vs 14.5 mo
(p = 0.056)
Neutropenia: 46% vs 4%
FN: 2% vs <1% PN: 4% vs
<1% HFS: 0% vs 14%
Awada et al.
(2013)/Phase II
Etirinotecan q21da vs q14d 35 35 71% 49% 2
√ √
(90%)
√
/- 29% vs 29% 5.6 vs 3.3 mo  13.1 vs 8.8 mo  q21d regimen:
Neutropenia (delayed):
11% FN: <1% Diarrhea
(delayed): 21%
Perez et al. 2015 Etirinotecan vs TPC 429 423 100% (per
eligibility criteria)
3
√ √ √
16% vs 17% 2.4 vs 2.8 mo  12.4 vs 10.3 mo Neutropenia 10% vs
31% Diarrhea: 10% vs
1% Anemia 5% vs 5%
Fatigue 4% vs 4%
Abbreviations: FN, febrile neutropenia; HFS, hand–foot syndrome; MBC, metastatic breast cancer; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PN, peripheral neuropathy;
q14d,  every 2 weeks; q21d, every 3 weeks; q28d, every 4 weeks; TPC, therapy of physicians’ choice.
a Dose chosen for phase III study.
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gy in other ways by remodeling the tumor vasculature, reversing
pithelial-mesenchymal transition and decreasing the capacity of
umor cells for migration and invasion (Yoshida et al., 2014). These
on-classical effects may  explain, at least in part, the greater effect
f eribulin on OS than PFS or response rates.
The EMA  recently requested a joint analysis of the two phase
II trials that enabled a more detailed evaluation of eribulin in
arious subgroups. OS was prolonged by 2.4 months (HR 0.85
CI, 0.77–0.95]; p = 0.003) (Twelves et al., 2014b). The beneﬁts of
ribulin were maintained across subgroups, but were most robust
n patients with HER2-negative disease and appeared greatest in
atients with TNBC who gained an average of almost 5 months
n OS (HR 0.74 [CI, 0.60–0.92]; p = 0.006). Subsequently, the EMA
idened the approval for eribulin, moving it to the second-line
etting. The combination of eribulin and capecitabine also appears
o be highly effective and remarkably well tolerated as described
bove (Twelves et al., 2014a).
. Emerging new agents
Capecitabine and eribulin are currently the “go to” agents for
BC after anthracycline and taxane. Preliminary reports of pivotal
tudies with etirinotecan pegol and vinﬂunine have been presented
nd full publications are awaited (Table 1).
.1. Vinﬂunine
Vinﬂunine is a third-generation, ﬂuorinated vinca alkaloid that
as been studied in patients with MBC  after ﬁrst-line anthracycline-
nd taxane-based chemotherapy. In phase II trials, ORRs ranged
rom 12.5% to 30%, median PFS from 2.6 to 3.7 months, and
S from 11 to 14 months (Campone et al., 2006; Fumoleau
t al., 2009). Tolerability was reported as acceptable; nevertheless,
lmost two-thirds of patients, experience grade 3/4 neutropenia.
n a preliminary report of a large phase III trial single agent vinﬂu-
ine did not, however, improve survival compared to an alkylator of
hysician’s choice (9.1 and 9.3 months, respectively) (Cortes et al.,
015b).
Two recent MBC  trials have assessed vinﬂunine in combina-
ion with capecitabine or gemcitabine(Aapro et al., 2014; Jimenez
t al., 2014; Llombart et al., 2014). The addition of vinﬂunine
o capecitabine in women with MBC  previously treated with
r resistant to an anthracycline and a taxane prolonged PFS by
.3 months; this improvement was statistically signiﬁcant and
ssociated with less hand–foot syndrome but grade 3 or 4 neu-
ropenia was increased with the combination (Table 1) (Aapro et al.,
014; Jimenez et al., 2014). Vinﬂunine was also investigated as
n alternative to paclitaxel in combination with gemcitabine as
rst-line treatment for patients previously receiving anthracycline
Llombart et al., 2014). Non-inferiority with respect to PFS was
emonstrated for the vinﬂunine combination (HR 1.05), which was
lso less neurotoxic than the paclitaxel-gemcitabine combination.
here was, however, no difference in OS (19.1 months and 18.9
onths, respectively).
Vinﬂunine has not been approved by the regulatory authorities
or use in MBC.
.2. Etirinotecan pegol (NKTR-102)
Topoisomerase I (TOP1) inhibitors disrupt DNA replication in
ancer cells causing single strand, and eventually lethal double
trand, DNA breaks leading to cell death (Xu and Villalona-Calero,
002). TOP1 inhibition is a “validated” target but has been stud-
ed only to a limited extent in MBC  (Kumler et al., 2013). TOP1
nhibitors have a mechanism of action distinct from, and lack cross-
esistance with, cytotoxic agents currently used to treat MBC. Noogy/Hematology 100 (2016) 74–87 83
topoisomerase I inhibitors have been approved by the FDA or EMA
for the treatment of breast cancer.
In a systematic review of TOP1 inhibitors in 4 trials of 217
patients with refractory MBC  treated with single-agent irinotecan,
ORR ranged from 5% to 23%; primary grade 3/4 toxicities were neu-
tropenia, diarrhea, and nausea/vomiting (Kumler et al., 2013). Much
of the toxicity associated with irinotecan is due to high peak drug
concentrations with 3-weekly dosing (Gerrits et al., 1997). This
was reﬂected in a randomized phase II MBC trial in which weekly
irinotecan 100 mg/m2 appeared better tolerated and more active
(ORR 23%; median PFS, 2.8 months) than every 3-weekly treatment
at a dose of 240 mg/m2 (ORR 14%; median PFS, 1.9 months) (Perez
et al., 2004). This suggests that prolonged exposure to irinotecan,
and its active metabolite SN38, might be beneﬁcial.
Etirinotecan pegol is a long-acting polymer-engineered
molecule comprising irinotecan bound to a proprietary polyethy-
lene glycol core by a biodegradable linker that slowly hydrolyzes
in vivo to release SN38, the active moiety of irinotecan (Jameson
et al., 2013; Hoch et al., 2014). Etirinotecan pegol is designed to
provide continuous exposure to SN38 at the site of the tumor
through altered pharmacokinetics and by exploiting the enhanced
permeability and retention (EPR) effect. The principle is that the
high molecular weight of the parent drug will limit its ability to
freely cross the intact vasculature into healthy tissues; however,
because of the EPR effect in tumors, the macromolecule should
easily traverse the leaky tumor vasculature.
4.2.1. Pharmacology
Preclinical and initial clinical studies demonstrated a marked
contrast in the pharmacokinetic proﬁle of SN38 after treatment
with etirinotecan pegol compared to irinotecan(Jameson et al.,
2013; Hoch et al., 2014). Eritinotecan pegol achieved a maximum
plasma concentration (Cmax) of SN38 10-fold less than irinote-
can but the half-life of SN38 was much longer (50 days and
12–17 h for etirinotecan and irinotecan, respectively) (Jameson
et al., 2013). These pharmacokinetic characteristics would be
expected to reduce toxicities associated with the excessively high
SN38 concentrations but maintain efﬁcacy with tumor exposure
to SN38 throughout the treatment cycle. This was  conﬁrmed in
preclinical models with etirinotecan pegol achieving higher and
more sustained tumor concentrations of SN38 that correlated with
greater tumor growth inhibition in comparison to irinotecan (Hoch
et al., 2014). Interestingly, etirinotecan pegol penetrates, and is
retained in, TNBC brain metastases (Nounou et al., 2014); there
was a signiﬁcant reduction in both the size and number of brain
metastases, and etirinotecan pegol-treated animals had prolonged
survival (Hoch et al., 2014). These results are notable given the efﬁ-
cacy of etirinotecan pegol in patients with brain metastases in the
BEACON trial (see below).
4.2.2. Early clinical trials
Phase I trials of etirinotecan pegol revealed early evidence of
antitumor activity, including in MBC, over multiple dosing sched-
ules with signiﬁcantly different toxicity compared to irinotecan
(Hoch et al., 2014). A subsequent open-label randomized phase II
trial evaluated etirinotecan pegol 145 mg/m2 every 2 weeks (q14d)
or every 3 weeks (q21d) in patients failing prior taxane and receiv-
ing ≤2 previous chemotherapy regimens for MBC  (Awada et al.,
2013). The primary endpoint was  ORR. Ten of 35 patients in each
arm responded, with an ORR in the intention-to-treat (ITT) popu-
lation of 29% (95% CI 18.4–40.6). The median PFS was 4.7 months
(ITT population; 95% CI, 2.7–5.7 months), with more than a third
of patients (35.5%) progression-free at 6 months. Delayed diarrhea
was the most common serious toxicity (q14d: 69% all grades, 17%
grade 3, 3% grade 4; q21d: 77% all grades, 23% grade 3, no grade
4) and typically occurred after 3 months of therapy. Unfortunately,
84 C. Twelves et al. / Critical Reviews in Oncology/Hematology 100 (2016) 74–87
Fig. 1. Algorithmic approach to pretreated metastatic breast cancer utilizing sequential monotherapies.
Abbreviations: 1L, ﬁrst-line; A, anthracycline; EU, European Union; PLD, pegylated liposomal doxorubicin; T, taxane; US, United States.
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Limited if near maximum cumulative dose for cardiotoxicity or if cardiac risk facto
Limited if important residual neuropathy or history of severe neuropathy with pre
iarrhea management and dose reduction guidelines were not fol-
owed appropriately in more than half (59%) of patients. Other
rade 3/4 toxicities observed in >10% of patients across both sched-
les included fatigue (11%), dehydration (10%), and neutropenia
11%); febrile neutropenia occurred in 1 patient. Comparing the
wo etirinotecan pegol schedules, both PFS and OS were superior
ith the q21d schedule (Table 3), which was also associated with
ess drug-related ≥ grade 3 toxicity and fewer treatment discon-
inuations. The q21d schedule was, therefore, selected for further
tudy.
.2.3. The BEACON trial
First results of the phase III BEACON study (BrEAst Cancer Out-
omes with NKTR-102) comparing etirinotecan pegol with TPC
deﬁned as active single agent, consisting of eribulin, ixabepilone,
inorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel)
n 852 patients with MBC  who previously received an anthracy-
line, taxane, and capecitabine were recently reported (Perez et al., therapy.
2015). Stratiﬁcation factors included geographic region, prior use
of eribulin, and receptor status. The primary endpoint was OS;
additional endpoints were PFS, ORR, clinical beneﬁt rate, dura-
tion of response, pharmacokinetics, safety, health-related QOL,
and pharmacoeconomics. Additionally, key exploratory endpoints
included speciﬁc biomarkers (TOP1, topoisomerase 2, markers of
DNA damage/apoptosis) in circulating tumor cells (CTCs) using
ApoCell technology (Hoch et al., 2013); prespeciﬁed analyses also
include efﬁcacy assessments in poor prognostic subgroups (i.e.,
those with liver and/or stable brain metastases at study entry).
Although median survival was longer in the etirinotecan arm
by 2.1 months (12.4 months and 10.3 months, respectively; HR
0.87, P = 0.08), the trial did not meet its primary endpoint. Among
the prespeciﬁed subgroup of 67 patients with preexisting stable
brain metastases, there appeared to be particular OS beneﬁt from
etirinotecan pegol (10.0 and 4.8 months, respectively; HR 0.51,
P < 0.01), and 12-month survival was 44.4% and 19.4%, respectively.
Similarly, the group with liver metastasis (n = 456) also beneﬁted
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igniﬁcantly from etirinotecan pegol (OS 10.9 and 8.3 months,
espectively; HR 0.73, P < 0.002) (Perez et al., 2015). Analyses of
ubgroups deﬁned by baseline CTC biomarkers are awaited.
. Conclusions
Chemotherapy remains a mainstay of treatment for patients
ith MBC  treatment, regardless of the molecular phenotype. Fol-
owing anthracycline and taxane treatment many patients remain
andidates for further chemotherapy. Despite the number of cyto-
oxic agents available to clinicians, there exists a limited amount
f evidence-based randomized data and hence, uncertainty and a
ack of consensus on the optimal sequence of agents. Nevertheless,
 systematic approach is helpful for identifying which agents may
e utilized under what circumstances (Fig. 1).
Notwithstanding the emergence of newer targeted therapies
nd the emerging promise of immunotherapy, we argue that it
ould be premature to abandon attempts to develop new cyto-
oxic chemotherapy for the treatment of patients with MBC. On the
ther hand, new cytotoxic agents should not be “me  too” therapies.
ather, new cytotoxic agents should address speciﬁc challenges: (1)
ither a novel target, a novel interaction with an established target,
r a novel mode of delivery; (2) achieve meaningful improve-
ents in clinically relevant endpoints, preferably OS and/or QOL, in
ell-designed randomized phase III trials; and, (3) ideally should
dentify biomarker(s) predictive of beneﬁt or resistance.
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